
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 13
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT03258294 | Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease | ||
NCT00758927 | The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients | ||
NCT02305355 | Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia | ||
NCT02087722 | Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients | ||
NCT02035215 | Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia | ||
NCT02789592 | Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease | ||
NCT03482180 | Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled | ||
NCT00549692 | Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy | ||
NCT03222206 | The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease | ||
NCT03026933 | Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled | ||
NCT01450228 | Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients | ||
NCT02768077 | Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease | ||
NCT01813253 | Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer |